Neuraptive
Louisville, US · Founded 2017 · 2 known investors
Neuraptive develops therapeutics and medical products for peripheral nerve repair, including NTX-001, a surgical treatment kit for peripheral nerves following trauma or nerve reconstruction procedures. The company serves physicians and patients affected by peripheral nerve injuries in the U.S. market.
Founders & leadership
DJ
David JacksonNamed on SEC filing
GD
Gino DiSciulloNamed on SEC filing
RH
Randy HubbellNamed on SEC filing
Board
GP
IG
Ivan GergelinDirector Board of DirectorsManaging Partner and Chief Medical Officer at New Rhein Healthcare Investors, LLC
Investors · 2
Reported raises · per SEC filings
Form D private placements$29.8M disclosed across 4 rounds · 2017–2022
▶$19.5MraisedOct 2022 · 71 investors · BiotechnologyRule 506(b)
▶$19.5MraisedOct 2022 · 71 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Randy HubbellDirector
- Robert S RadieExecutive Officer, Director
- Greg ParekhDirector
- David PierceDirector
- Ivan GergelDirector
- David JacksonDirector
- Evan TzanisExecutive Officer
- Offering amount
- $38.1M
- Amount sold
- $19.5M
- Minimum investment
- $25K
- Sales commissions
- $1.1M
- Placement agents
- Maxim Group LLC
- First sale
- Sep 2022
- Incorporated
- Corporation, Pennsylvania
- Federal exemptions
- 06b
▶$10.2MraisedApr 2019 · 5 investors · BiotechnologyRule 506(b)
▶$10.2MraisedApr 2019 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David JacksonExecutive Officer, Director
- Gino DiSciulloDirector
- Greg ParekhDirector
- Ivan GergelDirector
- Randy HubbellDirector
- Offering amount
- $12.5M
- Amount sold
- $10.2M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$100KraisedAug 2018 · 1 investors · BiotechnologyRule 506(b)
▶$100KraisedAug 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David M JacksonExecutive Officer, Director
- Offering amount
- $100K
- Amount sold
- $100K
- Minimum investment
- $100K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$25KraisedAug 2017 · 1 investors · BiotechnologyRule 506(b)
▶$25KraisedAug 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David M. JacksonExecutive Officer
- Offering amount
- $1M
- Amount sold
- $25K
- Minimum investment
- $10K
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Neuraptive do?
- Neuraptive develops therapeutics and medical products for peripheral nerve repair, including NTX-001, a surgical treatment kit for peripheral nerves following trauma or nerve reconstruction procedures. The company serves physicians and patients affected by peripheral nerve injuries in the U.S. market.
- Who are Neuraptive's investors?
- Neuraptive's investors include Central Texas Angel Network, New Rhein Healthcare Investors, LLC.
- How much funding has Neuraptive raised?
- Neuraptive has disclosed $29.8M raised across 4 rounds.
- Where is Neuraptive headquartered?
- Neuraptive is headquartered in Louisville, US.